STADA Arzneimittel AG (SAZ) Given a €66.25 Price Target by Warburg Research Analysts
STADA Arzneimittel AG (ETR:SAZ) has been given a €66.25 ($77.94) target price by investment analysts at Warburg Research in a research note issued to investors on Friday. The firm currently has a “sell” rating on the stock.
A number of other equities research analysts have also recently commented on SAZ. Commerzbank Ag set a €66.00 ($77.65) price target on shares of STADA Arzneimittel AG and gave the stock a “neutral” rating in a report on Saturday, May 20th. Independent Research GmbH set a €66.00 ($77.65) price target on shares of STADA Arzneimittel AG and gave the stock a “neutral” rating in a report on Saturday, May 20th. S&P Global set a €66.00 ($77.65) price target on shares of STADA Arzneimittel AG and gave the stock a “neutral” rating in a report on Saturday, May 20th. Finally, Kepler Capital Markets set a €62.50 ($73.53) price objective on shares of STADA Arzneimittel AG and gave the company a “sell” rating in a report on Thursday, June 22nd. Two research analysts have rated the stock with a sell rating and three have issued a hold rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of €64.55 ($75.94).
Shares of STADA Arzneimittel AG (ETR SAZ) traded up 10.75% during trading on Friday, reaching €72.00. The company had a trading volume of 8,120 shares. The firm has a 50-day moving average of €64.57 and a 200-day moving average of €61.26. STADA Arzneimittel AG has a 12-month low of €41.40 and a 12-month high of €72.54. The company has a market cap of €4.48 billion and a P/E ratio of 47.59.
ILLEGAL ACTIVITY WARNING: “STADA Arzneimittel AG (SAZ) Given a €66.25 Price Target by Warburg Research Analysts” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/08/18/stada-arzneimittel-ag-saz-given-a-66-25-price-target-by-warburg-research-analysts.html.
About STADA Arzneimittel AG
Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products.
Receive News & Ratings for STADA Arzneimittel AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel AG and related companies with MarketBeat.com's FREE daily email newsletter.